Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 41 to 50 of 858 total matches.
Rosiglitazone (Avandia) Revisited
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010 (Issue 1333)
EDITOR IN CHIEF: Mark Abramowicz, M.D.
EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F ...
The cardiovascular safety of the thiazolidinedione rosiglitazone (Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York Times, February 19, 2010).
Dutasteride (Avodart) for Prevention of Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Apr 19, 2010 (Issue 1336)
., M.P.H., F.A.C.P., Harvard Medical
School
EDITOR: Jean-Marie Pflomm, Pharm.D.
ASSISTANT EDITORS ...
A study recently published in the New England Journal of Medicine concluded that dutasteride (Avodart –
GlaxoSmithKline), a 5α-reductase inhibitor marketed for treatment of symptomatic benign prostatic hyperplasia, reduced the risk of prostate cancer over a 4-year period.
In Brief: Herpes Zoster Vaccine (Zostavax) Revisited
The Medical Letter on Drugs and Therapeutics • May 31, 2010 (Issue 1339)
EDITOR IN CHIEF: Mark Abramowicz, M.D.
EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F ...
The 2006 Medical Letter article on the then-new varicella-zoster vaccine concluded that Zostavax appears to be safe and effective in protecting patients ≥60 years old against herpes zoster and postherpetic neuralgia, especially in reducing the severity and duration of the disease.1 Some new information has recently become available.CLINICAL STUDIES — A Veterans Administration randomized, double-blind trial enrolled more than 38,000 patients ≥60 years old and followed them for a mean of 3.4 years after administration of Zostavax or placebo. Since the efficacy of the vaccine had been...
Bioidentical Hormones
The Medical Letter on Drugs and Therapeutics • May 31, 2010 (Issue 1339)
.
EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical
School
EDITOR: Jean-Marie ...
In recent years, many women have become concerned about the safety of pharmaceutical replacement
hormones for treatment of menopausal symptoms. “Bioidentical” hormone preparations, which are not approved by the FDA, are heavily promoted in popular books and on TV as alternatives; these are
derivatives of soy or plant extracts, chemically modified to be structurally identical to endogenous hormones.
Most FDA-approved single-entity hormones are also derivatives of soy or plant extracts and are
structurally identical to hormones produced by the ovary.
Copyright Violations
The Medical Letter on Drugs and Therapeutics • Apr 29, 2002 (Issue 1129)
Meinertz, M.D.,
University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F ...
The Medical Letter is a nonprofit organization supported entirely by subscription fees and sales of books, software and individual issues. We do not accept advertisements, grants, donations or gifts. We do not sell large numbers of reprints to pharmaceutical manufacturers.
We ask our readers to respect our copyright. We offer electronic access to our issues to individual subscribers and, for a reasonable fee, site licenses for electronic access to organizations like pharmaceutical companies and universities.
Prevention and Treatment of Heat Injury
The Medical Letter on Drugs and Therapeutics • Jul 21, 2003 (Issue 1161)
injury, which has occurred at ambient temperatures as low as 16°C
(about 60°F). The risk of injury rises ...
Summer heat waves cause thousands of cases of heat-related illness in the US each year and hundreds of heat-related deaths, especially among the elderly. This review describes the contributing factors, clinical signs, and ways to prevent and treat heat injury.
Safety of Smoking Cessation Drugs
The Medical Letter on Drugs and Therapeutics • Aug 24, 2009 (Issue 1319)
., M.P.H., F.A.C.P., Harvard Medical
School
EDITOR: Jean-Marie Pflomm, Pharm.D.
ASSISTANT EDITORS ...
The most effective drugs available for treatment of tobacco dependence are bupropion (Zyban, and others and varenicline (Chantix). The FDA recently ordered the manufacturers of both to add boxed warnings about the risk of psychiatric symptoms and suicide to their prescribing information (FDA Alert, 7/1/2009).
Calcitriol (Vectical) for Mild to Moderate Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009 (Issue 1320)
., M.P.H., F.A.C.P., Harvard Medical
School
EDITOR: Jean-Marie Pflomm, Pharm.D.
ASSISTANT EDITORS ...
The FDA has approved calcitriol ointment (Vectical - Galderma), a vitamin D analog, for topical treatment of mild-to-moderate plaque psoriasis in adults ≥18 years old. Ointments are generally considered more potent than creams or solutions.
Resveratrol
The Medical Letter on Drugs and Therapeutics • Sep 21, 2009 (Issue 1321)
., M.P.H., F.A.C.P., Harvard Medical
School
EDITOR: Jean-Marie Pflomm, Pharm.D.
ASSISTANT EDITORS ...
Resveratrol is a phytochemical found in the skin of red grapes and in many other plants, including berries, plums and peanuts. As a constituent of red wine, it has been associated with cardioprotective effects. Dietary supplements containing resveratrol are now being widely promoted as antioxidants that can prevent agerelated diseases.
Combination Oral Contraceptives and the Risk of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • Mar 22, 2010 (Issue 1334)
.
EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical
School
EDITOR: Jean-Marie ...
Combination oral contraceptives increase the risk of venous thromboembolism (VTE). Their benefits, in
addition to preventing pregnancy, include lowering the risk of ovarian and endometrial cancer, reducing dysfunctional uterine bleeding and increasing serum hemoglobin concentrations. Are these benefits worth
the risk? And are some combination oral contraceptives safer than others?